Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Street View: Next-generation drugs bolster Lilly's growth outlook

By Reuters News

** Eli Lilly LLY.N raised annual revenue forecast by $5 billion and beat Wall Street estimates for third-quarter profit on Thursday, helped by robust demand for its weight-loss treatments

** Median PT of 33 brokerages covering the stock is $1,410 - LSEG data

NEW PIPELINE CATALYSTS

** Jefferies ("buy", PT: $1,610) says LLY's GLP-1 and obesity franchise could continue to exceed expectations through 2026 and beyond, driven by pricing and volume growth, with international obesity opportunities and the Medicare Bridge Program providing additional upside

** Truist Securities ("buy", PT: $1,612) says company's expanding diabetes and obesity drug portfolio, including pipeline treatments such as retatrutide and EloraTZP (next-generation obesity drug), should help sustain its market leadership, while advances in neuroscience, immunology and oncology support growth

** J.P.Morgan ("overweight", PT: $1,650) says LLY remains its top pick, expecting earnings upside as it extends its lead in the incretin market and delivers key pipeline milestones across several non-obesity opportunities

** Morningstar (fair value: $980) says pipeline candidates EloraTZP and retatrutide are expected to be key growth drivers for LLY, as company continues to raise the bar on treatment efficacy and tolerability

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.